RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsAs discussed, ONCY's pelareorep has a proven ablility to remodel an immunosuppressive tumor microenvironment (TME), particularly in solid tumors, and the "priming" of the immune system in advance of the addition of a checkpoint inhibitor, like pembrolizumab, atezolizumab, sasanlimab, anti-CD47, etc., for example.
https://pubmed.ncbi.nlm.nih.gov/34599020/